Banyan Partners’s Array Biopharma Inc ARRY Stock Holding History

Banyan Partners’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-10,320	Closed	-$65K	–	453
2013 Q3	$65K	Buy	+10,320	New	+$61.3K	0.01%	334

Other funds holding ARRY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Banyan Partners's ARRY Position: Q4 2013 in Review

Banyan Partners sold out of Array Biopharma Inc (ARRY) in Q4 2013, closing a stake of 10,320 shares — an estimated $65K sold.

Banyan Partners first reported a position in ARRY in Q3 2013 and held it in 1 quarter. The position peaked at $65K in Q3 2013. 143 funds tracked by Wall St. Rank hold ARRY as of Q4 2013.

Banyan Partners reported no remaining Array Biopharma Inc position as of Q4 2013 after selling out during the quarter.
Banyan Partners sold 10,320 Array Biopharma Inc shares in Q4 2013, an estimated $65K.
Banyan Partners first reported a position in Array Biopharma Inc in Q3 2013 and held it in 1 quarter.
Banyan Partners's Array Biopharma Inc position peaked at $65K in Q3 2013.
143 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2013.

Based on Banyan Partners's 13F filing for Q4 2013, filed 12 Feb 2014.